GUJARAT TERCE LABORATORIES LTD.

Gujarat Terce Laboratories Ltd has announced the closure of its trading window for designated persons and their immediate relatives. This closure is effective from October 1, 2026, and will continue until 48 hours after the declaration of the company's unaudited financial results for the second quarter ending September 30, 2026. The company will announce the date of the board meeting to consider these results in due course. This measure is in compliance with SEBI (Prohibition of Insider Trading) Regulations, 2015, and the company's internal code of conduct.

Gujarat Terce Laboratories Ltd announced the re-appointment of Mr. Aalap Prajapati as Managing Director & CEO for a term of three years, effective October 28, 2026, to October 27, 2029. The approval was granted by the company's members at the 41st Annual General Meeting held on August 21, 2026. Mr. Prajapati brings over 15 years of experience in the pharmaceutical sector, with expertise in business strategy, operations, marketing, and business development. He holds a management qualification from B.K. School of Business Management. The disclosure also notes his relationship as son to Mr. Natwarbhai Prajapati, a Whole-Time Director.

Gujarat Terce Laboratories Ltd has issued a corrigendum to its earlier intimation regarding the re-appointment of Mr. Aalap Prajapati as Managing Director & Chief Executive Officer. The company clarified that the re-appointment tenure is for three years, from October 28, 2026, to October 27, 2029, correcting an inadvertent error in the previously stated five-year tenure. The shareholders approved the three-year term at the 41st Annual General Meeting held on August 21, 2026. All other details from the original intimation remain unchanged.

Gujarat Terce Laboratories Limited announced its Unaudited Standalone Financial Results for the first quarter ended 30 June 2026. The Board of Directors approved these results, which have undergone a Limited Review by the Statutory Auditor, Shah Doshi Patel & Associates LLP. The company prepares its financial statements in accordance with Indian Accounting Standards (Ind AS). The results are for a single segment, Pharmaceuticals.

Gujarat Terce Laboratories Limited announced its Unaudited Standalone Financial Results for the first quarter ended 30 June 2026. The Board of Directors approved these results, which have undergone a Limited Review by the Statutory Auditor, Shah Doshi Patel & Associates LLP. The company prepares its financial statements in accordance with Indian Accounting Standards (Ind AS). The results are for a single segment, Pharmaceuticals.

Gujarat Terce Laboratories Ltd has announced a Board of Directors meeting scheduled for August 7, 2026. The primary agenda is to consider and approve the Unaudited Standalone Financial Results for the first quarter ended June 30, 2026. These results will be subject to a limited review by the company's statutory auditor. In line with the company's Insider Trading Code, the trading window will remain closed from July 1, 2026, to August 9, 2026, inclusive. The company will also upload this intimation on its website.

Gujarat Terce Laboratories Limited has announced that its 41st Annual General Meeting (AGM) will be conducted on August 21, 2026, commencing at 12:00 noon. The meeting will be held entirely through Video Conferencing or any other Audio-Visual Means facility, adhering to modern communication standards. The company's annual report for 2025-26, themed 'Building Relationships. Nurturing Brands.', emphasizes the importance of trust, enduring relationships with doctors, reach to every shelf, and reputation in building strong pharmaceutical brands. The report highlights that the company has spent forty years cultivating these relationships, leading to brands with a quarter-century of prescription loyalty.

Gujarat Terce Laboratories Limited has released its Annual Report for the Financial Year 2025-26. The report highlights the company's long-standing commitment to building relationships and nurturing brands within the pharmaceutical sector. It emphasizes the importance of trust earned through consistent quality and dedicated service, which has fostered strong loyalty from doctors, chemists, and patients over forty years. The company's strategy focuses on strengthening its invisible infrastructure of relationships, reach, and reputation, which it believes sets it apart in the industry and ensures the endurance of its brands.

Gujarat Terce Laboratories Ltd has announced the closure of its trading window for designated persons and their immediate relatives. This closure is effective from July 1, 2026, and will continue until 48 hours after the declaration of the company's unaudited financial results for the first quarter ending June 30, 2026. The trading window will reopen once the mandatory closure period concludes. The date of the board meeting to consider these financial results will be communicated separately.

Gujarat Terce Laboratories Ltd has amended its Code of Practices and Procedures for Fair Disclosure of Unpublished Price Sensitive Information, in compliance with Regulation 8(2) of the SEBI (Prohibition of Insider Trading) Regulations, 2015. The amended code incorporates recent amendments to the SEBI regulations and is available on the company's website.